Top Stories
Top Stories
Market Insider

After-hours buzz: Synnex, Dyax, Novavax & more

Check out the companies making headlines after the bell Tuesday:

A trader works on the floor of the New York Stock Exchange.
Getty Images

Synnex - Shares fell about 3 percent after the company missed analysts' expectations and issued weak second-quarter guidance. The IT service provider reported adjusted first quarter earnings of $1.46 a share, missing forecasts for $1.52 a share, on revenue of $3.20 billion, which was well below the $3.43 billion Wall Street had expected.

Novavax - Shares of the clinical-stage vaccine company edged lower after it closed a public offering of 28 million shares of common stock, netting the company about $201 million in gross proceeds.

Dyax - The biopharmaceuticals firm announced positive results from an early-stage trial of its hereditary angioedema treatment, DX-2930. The stock surged about 37 percent in after-hours trading.

Rubicon Project - Shares rose about 1 percent after the big data computing provider reached an agreement to acquire Chango, a provider of marketing technology, in a deal valued at around $122 million. Shares rose about 1 percent after the announcement.